Adjuvant treatment for pancreatic ductal carcinoma
- 533 Downloads
Pancreatic ductal adenocarcinoma (PDAC) is a tumor with a very poor prognosis. Most of the patients are diagnosed in advanced stages of the disease, and 5-year survival rates in these patients remains <10%. Surgery still remains the only radical treatment option, although only 15–20% of patients are candidates for surgical resection at the time of the diagnosis. Patients who undergo radical surgery still have a limited survival rate, being the average of 23 months. Three clinical trials have shown that adjuvant chemotherapy therapy after surgery may improve survival: CONKO-1, ESPAC-3, and ESPAC-4. Adjuvant therapy is recommended in patients with R0/R1, T1-4/N1-0 tumors and with ECOG 0-1. In patients with ECOG-2, the decision needs to be individualized. Treatment schemes that have demonstrated efficacy include gemcitabine alone, 5-fluorouracil, or the combination of gemcitabine and capecitabine for six months. Prior to adjuvant treatment, the following test are recommended: Complete blood tests, including CA19.9 biomarker; imaging studies to rule out early disease relapse (preferable thorax-abdomen-pelvic CT). Studies that have evaluated the efficacy of radiation therapy in the adjuvant setting have presented conflicting results. Its use should be considered in patients with R1 or R2 tumors or in those with lymph nodes involved.
KeywordsAdjuvant Pancreatic ductal adenocarcinoma Neoadjuvant Surgery Chemotherapy Radiotherapy
The authors thank Sofía Perea, Pharm D, PhD, for her support in writing the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare to have no conflict of interest.
The support for medical writing was supported by Fundación ECO.
Research involving human participants and/or animals
- 1.http://seer.cancer.gov/statfacts/html/pancreas.html, accessed February 4, 2016
- 2.GLOBOCAN. European age-standardised rates calculated by the statistical information team at cancer research UK, 2011 using data from GLOBOCAN 2008 v1.2, IARC, version 1.2. http://globocan.iarc.fr, accesed February 2016
- 7.Neoptolemos JP, Palmer D, Ghaneh P, Valle JW, Cunningham D, Wadsley J, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24.CrossRefPubMedGoogle Scholar
- 8.NCCN (National Comprehensive Cancer Network). NCCN clinical practice guidelines in oncology: pancreatic adenocarcinoma, v2.2015.Google Scholar
- 10.Duelge K, Krepline AN, Mahmoud A (2014) Survival benefit of adjuvant therapy for resectable pancreatic cancer (RPC) patients treated with neoadjuvant Therapy. Oncology 67th annual Cancer Symposium of the Society of Surgical Oncology Phoenix. Annals of Surgical Oncology, Poster P173Google Scholar
- 12.Berger AC, Garcia M, Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26:5918–22.CrossRefPubMedPubMedCentralGoogle Scholar
- 23.Herman JM, Swartz MJ, Hsu CC. Analysis of fluoruracil based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large prospectively collected database at the Johns Hopkins Hospital. J CLin Oncol. 2008;26:3503–10.CrossRefPubMedPubMedCentralGoogle Scholar
- 24.Sinn M, Riess H, Sinn B, Stieler JM, Pelzer U, Striefler JK, et al. Human equillibrative nucleoside transporter 1 expression analysed by the clone SP 120 rabbit antibody is not predictive in patients with pancreatic cancer treated with adjuvant gemcitabine- results from the CONKO-001 trial. Eur J Cancer. 2015;51:1546–54.CrossRefPubMedGoogle Scholar
- 25.Greenhalf W, Ghaneh P, Neoptolemos J, Palmer DH, Cox TF, Lamb RF, et al (2014) Pancreatic Cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. JNCI 106: djt347Google Scholar